Urogen Pharma (NASDAQ:URGN) Reaches New 1-Year High - Time to Buy?

Key Points

• Urogen Pharma reached a new 52-week high of $19.89, experiencing positive trading momentum with a current trading price of $19.32.
• Analysts generally have a positive outlook on the stock, with an average target price of $32.86 and several "buy" ratings issued by brokerages, including a recent upgrade to $30.00 from Guggenheim.
• Despite strong analyst ratings, Urogen Pharma reported a loss of $0.92 earnings per share in its last quarterly report, missing estimates and indicating challenges in profitability.

Urogen Pharma (NASDAQ:URGN - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $19.89 and last traded at $19.32, with a volume of 1413 shares traded. The stock had previously closed at $19.40.

Analysts Set New Price Targets

Several brokerages recently issued reports on URGN. The Goldman Sachs Group set a $16.00 price target on Urogen Pharma and gave the stock a "neutral" rating in a report on Friday, June 13th. HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Urogen Pharma in a report on Tuesday, July 8th. Oppenheimer set a $31.00 price target on Urogen Pharma and gave the stock a "buy" rating in a report on Friday, June 13th. Guggenheim reiterated a "buy" rating and set a $30.00 price target (up previously from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. Finally, D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of Urogen Pharma in a report on Tuesday. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $32.86.

Urogen Pharma Stock Performance

The stock has a market cap of $820.05 million, a P/E ratio of -5.35 and a beta of 1.12. The business has a 50 day simple moving average of $14.05 and a 200-day simple moving average of $11.34.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.20). The business had revenue of $24.22 million during the quarter, compared to the consensus estimate of $23.06 million. Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. On average, sell-side analysts predict that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, General Counsel Jason Drew Smith sold 7,522 shares of the company's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total transaction of $143,971.08. Following the transaction, the general counsel owned 41,492 shares of the company's stock, valued at $794,156.88. This represents a 15.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Schoenberg sold 5,162 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $7.37, for a total value of $38,043.94. Following the transaction, the insider directly owned 153,378 shares in the company, valued at $1,130,395.86. This represents a 3.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 17,833 shares of company stock worth $280,567 in the last ninety days. Insiders own 4.70% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Urogen Pharma by 216.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company's stock valued at $48,227,000 after buying an additional 2,983,368 shares during the last quarter. RTW Investments LP lifted its position in shares of Urogen Pharma by 1.3% during the 4th quarter. RTW Investments LP now owns 3,834,794 shares of the company's stock valued at $40,841,000 after buying an additional 47,447 shares during the last quarter. RA Capital Management L.P. purchased a new position in shares of Urogen Pharma during the 1st quarter valued at $35,461,000. Vestal Point Capital LP lifted its position in shares of Urogen Pharma by 32.1% during the 1st quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company's stock valued at $23,812,000 after buying an additional 522,957 shares during the last quarter. Finally, Toronto Dominion Bank purchased a new stake in Urogen Pharma during the 4th quarter worth about $18,628,000. Hedge funds and other institutional investors own 91.29% of the company's stock.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.